Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2026-05-21 AGM Information
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Bulletin from the Annual General Meeting in Cantargia AB (publ)
AGM Information Classification · 95% confidence The document is a press release titled “Bulletin from the Annual General Meeting in Cantargia AB (publ)” and lists the resolutions adopted at the AGM (election of board members, approval of financial statements, remuneration, incentive schemes, share authorizations, etc.). It does not contain detailed financial statements but rather the meeting outcomes. This falls squarely under AGM Information rather than an actual annual report, interim report, or voting percentage declaration. Hence, AGM-R is the appropriate code.
2026-05-21 English
Kommuniké från årsstämma i Cantargia AB (publ)
AGM Information Classification · 95% confidence The document is a post-AGM press release (“Kommuniké från årsstämma”) summarizing the resolutions adopted at Cantargia AB’s Annual General Meeting, including board elections, auditor election, remuneration guidelines, and share issuance authorizations. It does not present full financial statements or detailed vote tallies, but rather the meeting outcomes, fitting the AGM Information category.
2026-05-21 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Delårsrapport Januari – mars 2026' which translates to 'Interim Report January – March 2026'. It contains detailed financial information such as net revenue, operating results, profit after tax, earnings per share, and liquidity figures for the first quarter of 2026. It also includes management commentary, project portfolio details, clinical study updates, and strategic developments. The length is substantial (15,000 characters), and the content includes actual financial statements and substantive analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). There is no indication that this is merely an announcement or a certification, and it is not a full annual report. Therefore, the correct classification is IR with high confidence. Q1 2026
2026-05-19 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report January – March 2026' and contains detailed financial information such as Statement of Comprehensive Income, Statement of Financial Position, Statement of Changes in Equity, Statement of Cash Flow, and notes. It also includes management commentary on clinical progress, strategic updates, and pipeline information. The length is about 15,000 characters, indicating a substantive report rather than a brief announcement. The content covers a quarterly period (Q1 2026), consistent with an interim or quarterly report. There is no indication that this is an annual report, audit report, or earnings release (which would be shorter and more summary). The presence of comprehensive financial statements and detailed analysis confirms it is an Interim / Quarterly Report (IR). Q1 2026
2026-05-19 English
Annual Report 2025
Annual Report Classification · 100% confidence The document is titled 'ÅRSREDOVISNING' (Annual Report) for Cantargia AB for the year 2025. It contains comprehensive sections including a management report, financial statements (Rapport över totalresultat, Rapport över finansiell ställning, etc.), notes to the financial statements, and an audit report (Revisionsberättelse). The document length and structure confirm it is the full annual report, not an announcement or summary. FY 2025
2026-04-17 Swedish
Kallelse till årsstämma i Cantargia AB (publ)
Proxy Solicitation & Information Statement Classification · 82% confidence The document is a notice (“kallelse”) convening the Annual General Meeting of Cantargia AB, including the agenda, proposals, and voting instructions to shareholders (including proxy and postal voting procedures). This matches the definition of a Proxy Solicitation & Information Statement (PSI), which encompasses materials sent to shareholders to provide information and request votes for meetings. It is not simply AGM meeting slides or a post‐meeting report, nor is it a financial report or earnings release.
2026-04-17 Swedish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.